Fluoropyrimidine activity (Bos taurus)

From WikiPathways

Revision as of 10:32, 29 November 2019 by Fehrhart (Talk | contribs)
Jump to: navigation, search
4, 5, 10, 11, 14...2420DNA IncorporationLiver cellBasolateral membraneCancer cellReuptakeApical membraneEffluxDrug resistanceRNA Incorporation95-FUFdUTPFURCES1ApoptosisFUPA5-FUFdUMPTegafurABCC4dTMPRRM2ABCC4UPP1DPYSRRM1FUDRSLC22A7UPB1UCK1SMUG1UPP2FBAL5-fluorouracil (5-FU)FUTPFUDPFUTP5-FU5-hydroxytegafurABCG2DNA RepairTP53DHFUCYP2A6DHFRFolate Cycle5-dFCRFUMP5,10-MethylenetetrahydrofolateTK1MTHFRLeucovorinTYMPUPP2CES25-dFURPPATTYMSERCC2CapecitabineABCC5ABCC3FdUDPFPGSXRCC3dUMPFdUMPDPYDSLC29A1GGHFdUTPUCK2MIR29CTYMPTDGUMPSDihydrofolateUPP1CDA5131126, 9, 13, 29, 331825430, 36172, 7, 19378, 2621, 28, 343


Description

The main mechanism of 5-FU activation is conversion to fluorodeoxyuridine monophosphate (FdUMP) which inhibits the enzyme thymidylate synthase (TYMS), an important part of the folate-homocysteine cycle and purine and pyrimidine synthesis The conversion of 5-FU to FdUMP can occur via thymidylate phosphorylase (TYMP) to fluorodeoxyuridine (FUDR) and then by the action of thymidine kinase to FdUMP or indirectly via fluorouridine monophosphate (FUMP) or fluroridine (FUR) to fluorouridine diphosphate (FUDP) and then ribonucleotide reductase action to FdUDP and FdUMP. FUDP and FdUDP can also be converted to FUTP and FdUTP and incorporated into RNA and DNA respectively which also contributes to the pharmacodynamic actions of fluoropyrimidines. Sources: PharmGKB:Fluoropyrimidine Pharmacokinetics, PharmGKB:Fluoropyrimidine Pharmacodynamics, Wikipedia:Fluorouracil

Comments

HomologyConvert 
This pathway was inferred from Homo sapiens pathway WP1601(80157) with a 89.0% conversion rate.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T; ''Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).''; J Pharm Pharmacol, 2005 PubMed Europe PMC Scholia
  2. Longley DB, Harkin DP, Johnston PG; ''Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study.''; Neoplasma, 1976 PubMed Europe PMC Scholia
  3. Yen-Revollo JL, Goldberg RM, McLeod HL; ''Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?''; Clin Cancer Res, 2008 PubMed Europe PMC Scholia
  4. Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL; ''Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.''; Clin Cancer Res, 2005 PubMed Europe PMC Scholia
  5. De Mattia E, Toffoli G; ''C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.''; Eur J Cancer, 2009 PubMed Europe PMC Scholia
  6. Marsh S; ''Thymidylate synthase pharmacogenetics.''; Invest New Drugs, 2005 PubMed Europe PMC Scholia
  7. van Kuilenburg AB, Meinsma R, Zonnenberg BA, Zoetekouw L, Baas F, Matsuda K, Tamaki N, van Gennip AH; ''Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.''; Clin Cancer Res, 2003 PubMed Europe PMC Scholia
  8. Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z; ''Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.''; Cancer Chemother Pharmacol, 2009 PubMed Europe PMC Scholia
  9. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, Selfridge J, Schär P; ''Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.''; PLoS Biol, 2009 PubMed Europe PMC Scholia
  10. Behera RK, Nayak R; ''Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil.''; Cancer Invest, 2009 PubMed Europe PMC Scholia
  11. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG; ''Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.''; Cancer Res, 2006 PubMed Europe PMC Scholia
  12. Nordgard SH, Alnaes GI, Hihn B, Lingjaerde OC, Liestøl K, Tsalenko A, Sørlie T, Lønning PE, Børresen-Dale AL, Kristensen VN; ''Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.''; Int J Cancer, 2008 PubMed Europe PMC Scholia
  13. Gusella M, Padrini R; ''G>C SNP of thymidylate synthase with respect to colorectal cancer.''; Pharmacogenomics, 2007 PubMed Europe PMC Scholia
  14. Peters EJ, Kraja AT, Lin SJ, Yen-Revollo JL, Marsh S, Province MA, McLeod HL; ''Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity.''; Pharmacogenet Genomics, 2009 PubMed Europe PMC Scholia
  15. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E; ''Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells.''; Cancer Res, 2004 PubMed Europe PMC Scholia
  16. Sobrero AF, Aschele C, Bertino JR; ''Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.''; J Clin Oncol, 1997 PubMed Europe PMC Scholia
  17. Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G; ''Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.''; Cancer Res, 2002 PubMed Europe PMC Scholia
  18. An Q, Robins P, Lindahl T, Barnes DE; ''5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.''; Cancer Res, 2007 PubMed Europe PMC Scholia
  19. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB; ''Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.''; Pharmacogenet Genomics, 2007 PubMed Europe PMC Scholia
  20. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P; ''MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins.''; Proc Natl Acad Sci U S A, 2008 PubMed Europe PMC Scholia
  21. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M; ''Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.''; Pharmacogenomics J, 2008 PubMed Europe PMC Scholia
  22. Diasio RB, Harris BE; ''Clinical pharmacology of 5-fluorouracil.''; Clin Pharmacokinet, 1989 PubMed Europe PMC Scholia
  23. Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C, Sasaki I; ''Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.''; Cancer Sci, 2009 PubMed Europe PMC Scholia
  24. Hagmann W, Jesnowski R, Faissner R, Guo C, Löhr JM; ''ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.''; Pancreatology, 2009 PubMed Europe PMC Scholia
  25. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H; ''Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.''; Eur J Cancer, 1998 PubMed Europe PMC Scholia
  26. Yuan JH, Cheng JQ, Jiang LY, Ji WD, Guo LF, Liu JJ, Xu XY, He JS, Wang XM, Zhuang ZX; ''Breast cancer resistance protein expression and 5-fluorouracil resistance.''; Biomed Environ Sci, 2008 PubMed Europe PMC Scholia
  27. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T; ''Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.''; Mol Cancer, 2006 PubMed Europe PMC Scholia
  28. Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR; ''ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.''; BMC Cancer, 2008 PubMed Europe PMC Scholia
  29. Jensen SA, Vainer B, Witton CJ, Jørgensen JT, Sørensen JB; ''Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.''; Acta Oncol, 2008 PubMed Europe PMC Scholia
  30. Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M; ''Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.''; Anticancer Res, 2007 PubMed Europe PMC Scholia
  31. Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, Okayama Y, Sugimoto Y, Oka T, Fukushima M; ''Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity.''; Biochem Biophys Res Commun, 2008 PubMed Europe PMC Scholia
  32. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA; ''Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.''; J Clin Oncol, 2006 PubMed Europe PMC Scholia
  33. Gmeiner WH; ''Novel chemical strategies for thymidylate synthase inhibition.''; Curr Med Chem, 2005 PubMed Europe PMC Scholia
  34. Huang ZH, Hua D, Li LH, Zhu JD; ''Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.''; J Cancer Res Clin Oncol, 2008 PubMed Europe PMC Scholia
  35. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D; ''Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.''; Mol Cancer Ther, 2009 PubMed Europe PMC Scholia
  36. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR; ''Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.''; Gastroenterology, 2009 PubMed Europe PMC Scholia
  37. Iacopetta B, Kawakami K, Watanabe T; ''Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?''; Int J Clin Oncol, 2008 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
117513view11:06, 21 May 2021EweitzModified title
108137view10:32, 29 November 2019FehrhartOntology Term : 'cancer pathway' added !
107075view14:16, 17 September 2019MaintBotChEBI identifier normalization
105995view11:52, 16 August 2019MaintBotHMDB identifier normalization
80928view15:31, 30 June 2015MkutmonNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
5,10-MethylenetetrahydrofolateMetabolite97272 (Chemspider)
5-FUMetaboliteCHEBI:46345 (ChEBI)
5-dFCRMetabolite
5-dFURMetabolite
5-fluorouracil (5-FU)MetaboliteCHEBI:46345 (ChEBI)
5-hydroxytegafurMetabolite
ABCC3GeneProduct
ABCC4GeneProductENSBTAG00000046611 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:10257
ABCC5GeneProductENSBTAG00000017666 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:10057
ABCG2GeneProductENSBTAG00000017704 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:9429
ApoptosisPathwayWP254 (WikiPathways)
CDAGeneProductENSBTAG00000006136 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:978
CES1GeneProductENSBTAG00000011021 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:1066
CES2GeneProductENSBTAG00000005093 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:8824
CYP2A6GeneProductENSBTAG00000047815 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:1548
CapecitabineMetaboliteCHEBI:31348 (ChEBI)
DHFRGeneProductENSBTAG00000007681 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:1719
DHFUMetabolite
DNA RepairPathwayWP1805 (WikiPathways)
DPYDGeneProductENSBTAG00000031358 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:1806
DPYSGeneProductENSBTAG00000021887 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:1807
DihydrofolateMetaboliteHMDB0001056 (HMDB)
ERCC2GeneProductENSBTAG00000002072 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:2068
FBALMetabolite
FPGSGeneProductENSBTAG00000008994 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:2356
FUDPMetabolite
FUDRMetabolite
FUMPMetabolite796-66-7 (CAS)
FUPAMetabolite
FURMetabolite
FUTPMetabolite
FUTPMetabolite8430967 (Chemspider)
FdUDPMetabolite
FdUMPMetabolite
FdUTPMetabolite
Folate CyclePathway
GGHGeneProductENSBTAG00000007534 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:8836
LeucovorinMetabolite
MIR29CRna
MTHFRGeneProductENSBTAG00000020698 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:4524
PPATGeneProductENSBTAG00000010571 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:5471
RRM1GeneProductENSBTAG00000013111 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:6240
RRM2GeneProductENSBTAG00000008216 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:6241
SLC22A7GeneProductENSBTAG00000006350 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:10864
SLC29A1GeneProductENSBTAG00000015131 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:2030
SMUG1GeneProductENSBTAG00000021974 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:23583
TDGGeneProductENSBTAG00000021633 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:6996
TK1GeneProductENSBTAG00000007121 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7083
TP53GeneProductENSBTAG00000001069 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7157
TYMPGeneProduct
TYMSGeneProductENSBTAG00000007003 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7298
TegafurMetabolite5193 (Chemspider)
UCK1GeneProductENSBTAG00000010810 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:83549
UCK2GeneProductENSBTAG00000044150 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7371
UMPSGeneProductENSBTAG00000013727 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7372
UPB1GeneProductENSBTAG00000001325 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:51733
UPP1GeneProductENSBTAG00000008428 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7378
UPP2GeneProductENSBTAG00000012801 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:151531
XRCC3GeneProductENSBTAG00000009966 (Ensembl) HomologyConvert: Homo sapiens to Bos taurus: Original ID = L:7517
dTMPMetaboliteHMDB0001056 (HMDB)
dUMPMetaboliteHMDB0001409 (HMDB)

Annotated Interactions

No annotated interactions
Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP3275"
Personal tools